Alpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare Conference
SEATTLE, WA –September 13, 2017– Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on the development of treatments for autoimmune/inflammatory diseases and cancer, announced today that the company will present at the Ladenburg Thalmann 2017 Healthcare Conference in New York on Tuesday, September 26, 2017, at 10:00am Eastern Time.
A live webcast of the presentation will be available online from the investors relations page of the company’s website at https://ir.alpineimmunesciences.com/events. After the webcast, an archive of the presentation will be available on the company website for 90 days.
About Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc. is focused on developing novel protein-based immunotherapies using its proprietary Variant Ig Domain™ vIgD™ platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which produces proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to cancer, autoimmune, and inflammatory diseases. Alpine has also developed TIP™ technology, based on the vIgD platform, to potentially enhance engineered cellular therapies. In October 2015, Alpine signed a worldwide research and license agreement with Kite Pharma, Inc. (NASDAQ:KITE) for up to $535 million in up front and potential milestone payments plus royalties on resulting sales. For more information visit www.alpineimmunesciences.com/.